Category Archives: Biochemistry

Biochemistry

Nautilus Biotechnology Expands Executive Team – BioSpace

Jan. 5, 2021 14:00 UTC

Proven leaders in product, finance, and marketing to accelerate the development of Nautilus next-generation, single-molecule proteomics analysis platform

SEATTLE & SAN CARLOS, Calif.--(BUSINESS WIRE)-- Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for quantifying the human proteome, today announced the addition of three new members to its executive leadership team: Subra Sankar, SVP of Product Development; Anna Mowry, VP of Finance and Business Operations; and Chris Blessington, VP of Corporate Marketing and Communications. These additions bolster the companys existing leadership team as Nautilus accelerates the development and ultimate commercialization of its platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005126/en/

Anna Mowry

Im incredibly excited to welcome Subra, Anna, and Chris to our team as each brings the type of seasoned operational leadership experience Nautilus will need for the next stages of our development, said Sujal Patel, co-founder and CEO of Nautilus Biotechnology. This expansion complements our already strong team and provides additional leadership in key functional areas.

Subra Sankar, SVP of Product Development Subra joins Nautilus from GenapSys where, as SVP of Product Development, he led the company's R&D efforts including Engineering, Assay, System Integration, Consumable Development, Informatics and a variety of chemistry and molecular biology groups. Subra has held many senior roles over the last 15 years, notably at Solexa/Illumina where, from 2006 to 2012, he led instrument and consumable development efforts for next gen sequencers and related products.

Anna Mowry, VP of Finance & Business Operations Anna joins Nautilus from Igneous where she served as VP of Finance and Operations with responsibility for finance, accounting, people, legal, and operations. Previously, Anna held a variety of roles at companies including Amazon Web Services, and Isilon Systems, where she ultimately led the finance and sales operations organization. Anna has an undergraduate degree in Biochemistry and started her career at the Fred Hutchinson Cancer Research Institute.

Chris Blessington, VP of Corporate Marketing and Communications Chris joins Nautilus from Smartsheet where he served as VP of Marketing and Communications with responsibility for creating markets, building awareness, and driving revenue. Prior to that, he led marketing and communications teams at ExtraHop Networks and Isilon Systems through the company's acquisition by EMC. At EMC/Isilon, he also served as executive sponsor of the companys Life Sciences and Genomics markets, leading product evangelism, market research, and sales preparedness.

ABOUT NAUTILUS BIOTECHNOLOGY

Based in Seattle, Washington with scientific development San Carlos, California, Nautilus is a biotechnology company who is developing a proteomics platform that aims to deliver superior sensitivity far more quickly, more completely, and less expensively than is currently possible. By breaking through the limitations of existing technologies, and effectively democratizing proteomics, Nautilus strategic mission is to enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and enhance opportunities for personalized and predictive medicine.

Learn more at: http://www.nautilus.bio

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005126/en/

Read the original here:
Nautilus Biotechnology Expands Executive Team - BioSpace

Biochemistry

Valinda Shirley Appointed as Executive Director Navajo Nation Environmental Protections Agency – lakepowelllife

Valinda Shirley Appointed as Executive Director Navajo Nation Environmental Protections Agency

Valinda Shirley

WINDOW ROCK, Ariz. Navajo Nation President Jonathan Nez and Vice President Myron Lizer announced the appointment of Valinda Shirley as the new Executive Director for the Navajo Nation Environmental Protection Agency. She replaces Oliver B. Whaley, who resigned in December to spend more time with his family.

Shirley resides in Rock Point, Ariz. with her husband and children. She is Tchiinii and born for Tz n. Her maternal grandfather is Bitahnii and her paternal grandfather is Taneeszhahnii. Prior to her appointment, she served as the Senior Remedial Project Manager for the Navajo Nation EPA Superfund Program coordinating on-site activities for environmental cleanup or remediation projects to ensure compliance with Navajo Nation and federal environmental laws, standards, regulations, and requirements including Din Fundamental Law.

With her upbringing, education, and professional experience, we are excited and confident that she will do a great job leading the Navajo Nation EPA. Her traditional upbringing combined with her formal education in biochemistry provides for a unique and very knowledgeable perspective on many issues related to protecting our environment for generations to come. We welcome her to our administration and look forward to working alongside her, said President Nez.

Shirley earned a Bachelors Degree in Biochemistry from the University of New Mexico and graduated as the valedictorian from Rock Point High School. Her previous professional experience also includes serving as an Environmental Compliance Technician with SWCA Environmental Consultants, Acting Business Manager and business consultant with Rock Point Community School, Environmental Specialist with the Navajo Nation EPA Waste Regulatory, Community Involvement Coordinator for the Phase 2 Removal Site Evaluation Trust, and the School Board Vice President for Rock Point Community School.

Shirley has a well-rounded background that will serve the Navajo Nation EPA and the Navajo people very well. Her scientific, environmental, and traditional knowledge have proven to be a strong foundation in the previous work she has done for the Navajo Nation. She also has expertise and experience in bridging partnerships and collaborations between the Navajo Nation and federal EPA. We commend her and look forward to working with her, said Vice President Lizer.

In her previous role with the Abandoned Uranium Mines projects, Shirley spearheaded the Northeast Church Rock Mine Site and the Tronox sites in Cove and Tse Tah, Ariz. She also advised the U.S. EPA concerning Navajo Nation laws and Din Fundamental Law as Applicable or Relevant & Appropriate Requirements (ARARs) used in the clean-up standards at the Mariano Lake, Mac and Black Mine Sites located in New Mexico. She also coordinated with the Nuclear Regulatory Commission on a Source Material License amendment for the United Nuclear Corporation mill site in the Eastern Navajo Agency.

I hold the Office of the Executive Director of the Navajo EPA in the highest regard, and I have the utmost respect for the agency and its employees. Since 1992, Navajo EPA has been the regulatory authority that safeguards Din bikyah d Nihookaa Dine. In my experience working with the agency, it has served as an integral part of government by ensuring Nihim Nahasdzaan d Nihitaa Ydihi are kept clean to the highest of standards for our seventh-generation grandchildren, said Shirley.

As the new Executive Director, Shirley said her goals include strengthening direct lines of communication with the Navajo people through community involvement and K, ensuring that currently funded AUMs progress to a level of clean-up with tangible results, and strategizing a way for the Navajo Nation to address the illegal dumping of refuse.

I will accomplish these goals by exercising stable leadership to create a team environment in the agency. Communication and k are also crucial in fulfilling these goals. I know this because these ideals are ingrained in me and practiced as a school board member representing four Navajo communities in the Northern Navajo Agency. I am familiar with fiduciary trust responsibilities and passionately believe that projects, legislation, and meaningful change can happen through teamwork and collaboration from all government branches, Shirley stated.

I view U.S. EPA and other federal agencies as partners of the Navajo EPA, and I also believe in the inviolability of our Navajo Nation laws. Navajo Nation laws and regulations are in place to protect the Din, especially when federal regulations become lax in their standards. In the past, only federal laws were used as across-the-board clean-up standards that failed in protecting the Din. Therefore, it is imperative to safeguard affected communities by ensuring that Navajo Nation laws and regulations are adhered to, she added.

Valinda Shirleys appointment is effective immediately and subject to confirmation by the Navajo Nation Council, in accordance with the Navajo Nation Code. Council Delegate Kee Allen Begay, Jr. will sponsor the bill for confirmation.

Read this article:
Valinda Shirley Appointed as Executive Director Navajo Nation Environmental Protections Agency - lakepowelllife

Biochemistry

Autobahn Therapeutics Strengthens its Team to Support its Continued Growth – BioSpace

Jan. 5, 2021 13:30 UTC

Scott Giacobello Appointed to Board of Directors

Scott Forrest, Ph.D., Promoted to Chief Financial Officer

SAN DIEGO--(BUSINESS WIRE)-- Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that industry veteran Scott Giacobello, chief financial officer of GW Pharmaceuticals, has been appointed to Autobahns board of directors and will serve as the chair of the companys audit committee. In addition, Scott Forrest, Ph.D., has been promoted to the role of chief financial officer from his current position as chief business officer.

Autobahns tunable brain-targeting chemistry platform and strong pipeline have the potential to transform the future of treatments for CNS disorders. I look forward to partnering with the exceptional leadership team and board to support a strong financial organization that will ensure the advancement of this important science, said Mr. Giacobello.

We are excited to welcome Mr. Giacobello to our board of directors. His extensive financial management and capital raising experience will prove valuable to our future growth and evolution, said Kevin Finney, chief executive officer of Autobahn. In addition, Dr. Forrest has played an instrumental role in the progress we have made across both our brain-targeting chemistry platform and pipeline addressing devastating CNS disorders, including adrenomyeloneuropathy and remyelination in multiple sclerosis. Following the completion of a successful pre-IND meeting for our lead program, ABX-002, his business strategy and financial leadership will be critical as we advance toward becoming a clinical-stage company.

Mr. Giacobello is an accomplished executive with more than 25 years of experience leading finance organizations. Prior to GW, he served as chief financial officer for Chase Pharmaceuticals Corporation, until it was acquired by Allergan, Inc. Earlier, Mr. Giacobello held senior level finance positions at Allergan, Inc., most recently serving as vice president of finance for global research & development. His previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP. Mr. Giacobello holds a B.A. in business administration from the University of Notre Dame and is a Certified Public Accountant.

Prior to joining Autobahn as chief business officer in July 2020, Dr. Forrest was chief operating officer and chief financial officer at Inception Therapeutics, a Versant Ventures discovery engine focused on building and operating transformative biotech companies. Earlier, he was a co-founder and vice president of operations and corporate development at BlackThorn Therapeutics and served as vice president of business development at The Scripps Research Institute. Dr. Forrest started his career at the University of North Carolina (UNC) where he led the restructuring, expansion and management of the life sciences licensing team. He also served as an entrepreneur in residence at UNC and was a central part of the successful launch of multiple startup companies, such as Epizyme. Dr. Forrest holds a B.S. in biochemistry from the University of Calgary and a Ph.D. in pharmacology from the University of Virginia.

About Autobahn Therapeutics Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Autobahn is leveraging its brain-targeting chemistry platform to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules. The companys pipeline is led by ABX-002, a thyroid hormone receptor beta agonist for the treatment of adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. For more information, visit http://www.autobahntx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005251/en/

View original post here:
Autobahn Therapeutics Strengthens its Team to Support its Continued Growth - BioSpace

Biochemistry

Global Calorimeters Market : Industry Analysis and Forecast (2019-2027) By Type, Industry, and Region. – LionLowdown

Global calorimeters marketsize was US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a CAGR of 11% during the forecast period.

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Market Definition

Calorimeter is an object, or a device used to measure the heat developed during chemical, electrical or mechanical reaction and is also used to calculate the heat capacity of materials. These devices are widely used in calorimetry science, which is the process of measuring specific heat capacity or enthalpy for both physical changes and chemical reactions in a certain system.

Market Dynamics

A growing use of calorimeter device for the study and research of chemistry, biochemistry and thermodynamics is major driving factor behind the growth of the market. The continuous advancements and developments in the instrumentation field, huge availability of specialized and advanced calorimeter in the market, rising demand for calorimeter from the industry professionals and academic researchers, escalating investments in the chemical and biochemical research sector and surge in the adoption advanced calorimeters in aerospace, automotive, nanotechnology, biomedical and biochemical, pharmaceutical and geology industries are expected to improve growth of the market during the forecast period.

However, the possibility of errors in measurements and high initial cost of the calorimeter are the major restraining factors that could hinder the growth of the market.

Global Calorimeters Market: Segmentation Analysis

By type, bomb calorimeter segment dominated the market in 2019 and is expected to keep its dominance at a CAGR of XX% during the forecast period. A bomb calorimeter is one of the most common and widespread types of constant-volume calorimeter which is generally used to measure combustion heat of a particular reaction. These calorimeters are usually tough and made of steel and they mostly make use of an oxygenated atmosphere for combustion purposes. Also, these calorimeters have capability to resist the explosive effects of both the exothermic release and the induced pressure during the reaction process, which make them the most ideal choice of variety of applications.

Alternatively, isothermal titration calorimeter segment is projected to witness fast growth at a CAGR of XX% during the forecast period. An increasing significance of these calorimeters in the field of biochemistry and pharmaceutical industry is expected to propel growth of the market during the forecast period.

By industry, biochemistry segment is projected to witness fast growth at a CAGR of XX% during the forecast period. From the past few years, the calorimetry technique is playing the most important historical role in the expansion of the chemical systems and is one of the oldest techniques in chemistry field. The surge in the adoption of calorimeters in biochemistry applications as it can facilitate purpose of substrate required for enzymes is accredited to the growth of the market.

Global Calorimeters Market: Regional Analysis

Region-wise, North America dominated the market in 2019 and is expected to maintain its dominance at a CAGR of XX% during the forecast period. The US and Canada are the major contributors behind the growth of the market in the region. The growth is attributed to the high adoption of calorimeters in chemical and medical applications.

Growing demand for bomb and differential scanning calorimeters for various applications, rising significance of calorimeters in waste-water analyzing equipment and processes and increasing need to measure heat capacity of materials in various industries are driving the growth of the market in NA region.

The objective of the report is to present a comprehensive analysis of the Global Calorimeters Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Calorimeters Market dynamics, structure by analyzing the market segments and projects the Global Calorimeters Market. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Calorimeters Market make the report investors guide.

Global Calorimeters Market Request For View Sample Report Page :@https://www.maximizemarketresearch.com/request-sample/74321

The Scope of Global Calorimeters Market

Global Calorimeters Market, By Type

Adiabatic Calorimeters Reaction Calorimeters Bomb Calorimeters Combustion of Non-Flammables Calvet-Type Calorimeters Constant-Pressure Calorimeter Differential Scanning Calorimeter Isothermal Titration CalorimeterGlobal Calorimeters Market, By Industry

Power Industry Biochemistry Coal & Petrochemical OthersGlobal Calorimeters Market, By Region

North America US Canada Europe UK France Germany Italy Spain Norway Russia Asia Pacific China India Japan South Korea Australia Malaysia Indonesia South America Brazil Mexico Argentina Middle East and AfricaGlobal Calorimeters Market, Key Players

Hanna Instruments, Inc TA Instruments METTLER TOLEDO Shimadzu Corporation Setaram Instrumentation Parr Instrument Company NETZSCH Instruments, Inc Yokogawa Electric Corporation ABB Malvern Panalytical Ltd Swan Analytische Instrumente AG Columbus Instruments COSMED Hitachi High-Technologies IKA MGC Diagnostics PhenoSys XX XX

Global Calorimeters Market Do Inquiry Before Purchasing Report Here @:https://www.maximizemarketresearch.com/inquiry-before-buying/74321

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:Name: Vikas GodageOrganization: Maximize Market Research Pvt.Ltd.PuneEmail:[emailprotected]Contact: +919607065656 / +919607195908Website:www.maximizemarketresearch.com

Original post:
Global Calorimeters Market : Industry Analysis and Forecast (2019-2027) By Type, Industry, and Region. - LionLowdown

Biochemistry

Texas A&M Names Outstanding Student Award Winners – Texas A&M University Today

Texas A&M Universitys Office of the Provost and the LAUNCH program have honored four seniors with the 2020 Outstanding Student Awards.

In a virtual ceremony held on campus, Paige Rigsby of Houston and Uzair Waheed of College Station each won the Brown-Rudder Award and Mary-Catherine Clark of Temple received the Gates-Muller Award. Each are valued at $5,000.

A new award this year the Class of 80 Selfless Service Award was presented to Lauren Breazeale of McKinney. It is valued at $4,000.

LAUNCH provides high-impact educational experiences and challengesstudents in all academic disciplines to graduate from an enriched, demanding curriculum. The programs administered by the office bring together outstanding students and faculty to build a community of knowledge-producers, life-long learners, nationally-recognized scholars and world citizens.

The Outstanding Student Awards are the pinnacle award for graduating seniors at Texas A&M, said Sumana Datta, assistant provost, executive director of LAUNCH and professor of biochemistry and biophysics.

Based on more than academics, the Brown Foundation-Earl Rudder Memorial Outstanding Student and the Robert Gates-Muller Family Outstanding Student awards recognize not just academic accomplishment, but just as importantly a depth of character demonstrated both publicly and privately, Datta said. The Class of 80 Selfless Service Award, given for the first time this year, recognizes one of Texas A&Ms core values and one for which our university and our students and former students are known for far and wide.

The Brown Foundation-Earl Rudder Memorial Outstanding Student Award was established in 1970 as the highest honor bestowed upon a graduating senior at Texas A&M. No more than two Brown-Rudder awardees are selected at Texas A&M each year. The award honors two outstanding senior students who exemplify the leadership, patriotism, fortitude, courage, humility, love of Texas A&M, and willingness to uphold the principles for which the university stands as vividly exemplified by James Earl Rudder during his lifetime. Gen. Rudder, a World War II hero, served as president of Texas A&M from 1959 until 1970.

The Robert Gates-Muller Family Outstanding Student Award was established in 2007 through a gift from the Muller family of Galveston to provide public recognition to an outstanding senior graduating from Texas A&M who has demonstrated those qualities of leadership, patriotism, courage and service to country, school and nation clearly exemplified by Robert M. Gates. Gates served as president of Texas A&M university from 2002 until 2006 when he was named U.S. Secretary of Defense.

The Class of 80 Selfless Service Award was established in 2019 and awarded for the first time this year to recognize an outstanding senior who exemplifies the selfless service and readiness to serve at a moments notice. The award memorializes the Aggie value of selfless service.

Read more here:
Texas A&M Names Outstanding Student Award Winners - Texas A&M University Today

Biochemistry

Garcia to head Department of Biochemistry and Molecular Biophysics – Washington University School of Medicine in St. Louis

Visit the News Hub

Renowned biochemist known for contributions to field of epigenetics

Benjamin Garcia, PhD, has been named head of the Department of Biochemistry and Molecular Biophysics at Washington University School of Medicine in St. Louis. His appointment is scheduled to begin July 1.

Benjamin A. Garcia, PhD, a noted leader in the field of biochemistry, especially for his work advancing mass spectrometry techniques, has been named head of the Department of Biochemistry and Molecular Biophysics at Washington University School of Medicine in St. Louis. Garcia, whose appointment tentatively is set to begin July 1, also will become the Raymond H. Wittcoff Distinguished Professor.

The schools Department of Biochemistry and Molecular Biophysics has an illustrious history as home to some of the nations most distinguished scientists, including scientific innovator Roy Vagelos, who headed the department then called the Department of Biological Chemistry from 1966-75 and went on to lead the development of cholesterol-lowering statin drugs at Merck; and Nobel laureates Carl Cori and Gerty Cori, known for their work showing how muscles manufacture and store energy. Understanding this process shed light on treatments for diabetes.

Garcia comes to Washington University from the University of Pennsylvania Perelman School of Medicine, where he is the John McCrea Dickson, MD, Presidential Professor in the Department of Biochemistry and Biophysics, and director of quantitative proteomics.

Dr. Garcia was selected from an impressive pool of candidates and was unanimously endorsed as the most exceptional person to launch the next era of advancing knowledge and discovery in this vitally important department, said David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean of the School of Medicine, and the Spencer T. and Ann W. Olin Distinguished Professor. We found ourselves energized by his vision for the department to continue to be at the forefront of the field and to leverage the breadth of collaborative opportunities within our biomedical research community. His personal research program, in proteomic analysis of epigenetic regulation, supports our long-term strategic institutional goal to transition our leadership in genomics into multi-omic systems medicine, which will serve as an engine producing the most imaginative approaches to personalized health care.

Garcias research has focused on developing new and advanced methods for using mass spectrometry and to analyze proteins called histones that help regulate DNA. Such analyses can shed light on basic biology and disease processes. His methods have revolutionized analysis of the proteins and genetics of cells from animal models and human samples. The research has led to important observations about the regulation of cell differentiation, growth of tissues, and the development of cancer. He has developed an extensive research network that has been supported by the National Institutes of Health (NIH) throughout his career. He is active in partnerships with industry, previously establishing a technology alliance partnership with Thermo-Fisher to develop advanced mass spectrometry instruments and methods.

After earning a bachelors degree from the University of California, Davis, Garcia pursued a doctorate in chemistry at the University of Virginia, where he had a specific interest in developing expertise in mass spectrometry, a technique used to analyze the sequence and composition of compounds and molecules, such as DNA. He continued his training with a postdoctoral fellowship at the University of Illinois, Urbana-Champaign. In 2008, he joined the faculty of Princeton University in the Department of Molecular Biology and was later recruited to the University of Pennsylvania School of Medicine in 2012.

Garcia also is known for his dedication to teaching, mentorship and increasing diversity in scientific research circles. He serves as vice chair for the biochemistry and molecular biophysics graduate program at Penn, a role that includes leadership in recruitment, outreach and promotion of diversity within the department. He also serves as chair of the University Council for Diversity and Equity at Penn and has developed strategies for attracting and supporting minority students into successful careers in science.

Garcia has been recognized for his research contributions with several honors including the NIH Innovator Award, the Presidential Early Career Award for Scientists and Engineers, the American Chemical Society Arthur F. Findeis Award, the Protein Societys Protein Science Young Investigator Award, the Human Proteome Organization Discovery in Proteomic Sciences Award and the prestigious American Society for Mass Spectrometry Biemann Medal, among numerous others.

He serves on the editorial boards of Molecular Omics, and the Journal of Proteome Research, and Molecular &Cellular Proteomics, and was formerly associate editor of BMC Genomics. He also served as chair of the Enabling Bioanalytical and Imaging Technology study section of the NIH and has served in other important national scientific leadership positions, including with the National Science Foundation Biological Science Advisory Committee, governing council for the World Human Proteome Organization, and board of directors for the U.S. Human Proteome Organization.

After leading the department for the past seven years, John A. Cooper, PhD, a professor of biochemistry & molecular biophysics, will step down from his position to focus on his laboratory research program.

We thank John Cooper for his exceptional, gracious and selfless leadership over the last seven years and through the remaining months of the coming academic year, Perlmutter said.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Follow this link:
Garcia to head Department of Biochemistry and Molecular Biophysics - Washington University School of Medicine in St. Louis

Biochemistry

Cardiovascular Testing Applications of Biochemistry – News-Medical.net

Tests that look at changes in biochemistry have an important application in medicine, including point-of-care cardiac testing and monitoring heart failure. Biochemical tests can also be used to determine if an individual is at risk of certain diseases, including cardiovascular disease.

Image Credit: Rattiya Thongdumhyu / Shutterstock.com

Acute myocardial infarction, where the blood supply to cardiac myocytes is compromised leading to cardiac myocyte death, is an important disease that results in morbidity and mortality across the world. Despite this, it is a condition that is often misdiagnosed, leading to either unnecessary death or inappropriate hospitalization. Therefore, it is important to establish a quick, reliable test that can accurately diagnose patients.

Currently, the diagnosis of myocardial infarction is typically achieved through the presence of symptoms such as chest pains and the use of ECG and cardiac troponin assay, which look for damage to the heart muscle. While cardiac troponin assay is a good biochemical test, it is thought that there is a delay in the increase of circulating cardiac troponins of around 3-4 hours.

This means that to ensure accurate diagnoses, this test needs to be repeated multiple times over 6-12 hours, which impacts how quickly treatment can be started. High-sensitivity cardiac troponin testing has become available, but an unexpected result of this was the discovery of other cardiac conditions.

Researchers have, therefore, been investigating other molecules that could potentially be used as a diagnostic test for acute myocardial infarction. One potential candidate for such a biochemical test is a heart-type fatty acid-binding protein (H-FABP). H-FABP is a small protein that is found in cardiac myocytes, and its small size and solubility mean that it is released faster from the cardiac myocytes compared to cardiac troponins.

Xu and co. carried out a meta-analysis investigating whether H-FABP is a good biomarker that can be used in a biochemical test for early diagnosis of acute myocardial infarction. Here, the authors looked at the results from 22 studies, which included a cumulative total of 6602 patients. The authors concluded that H-FABP testing is moderately accurate at diagnosing acute myocardial infarction between 3-6 hours after the onset of symptoms. However, when used in conjunction with high-sensitivity cardiac troponin testing, the sensitivity of the diagnostic testing was improved.

Heart failure is when the heart stops functioning effectively, leading to symptoms such as shortness of breath and fatigue. A biochemical test looking at the levels of B-type natriuretic peptide (BNP) has been used to diagnose and monitor patients with heart failure.

BNP is a peptide hormone, whose functions include vasodilation and smooth muscle relaxation. While BNP testing cannot replace a full assessment, it is a useful addition to diagnostic testing, in particular, to rule out heart failure in patients with symptoms such as breathlessness.

Oxytocin is a hormone that has various functions mainly related to fertility, such as the development of gonads and promoting romantic and parental behaviors, but studies have also noted that oxytocin also affects cardiometabolic function and is involved in stress-related disorders. Due to this, there is interest in developing a biochemical test to measure levels of oxytocin.

Various testing methods have been applied, but the most common are immunoassays; this group of biochemical tests includes enzyme-linked immunosorbent assays (ELISA). These tests have been performed on various starting materials, including serum, plasma, and saliva. However, currently, these are not fully validated and there are no standards available for these tests to become routine clinical biochemistry testing.

Apolipoproteins are an important part of lipoprotein metabolism, and they also act as templates for lipoprotein synthesis as well as aiding the maintenance of lipoprotein structure. Lipoproteins are involved in transporting triglycerides to different organs, maintaining extracellular cholesterol levels, and reverse cholesterol transport.

Abnormal lipoprotein metabolism has been linked to atherogenesis, obesity, insulin resistance, and diabetes. As such, studies have investigated whether testing for lipoproteins and apolipoproteins can be used to determine dyslipidemia and cardiovascular risk.

Two apolipoproteins, apolipoprotein A (apoA) and apolipoprotein B (apoB) are associated with cardiovascular risk; apoA is inversely linked, while apoB is positively linked to cardiovascular risk. Therefore, a biochemical test that looks at the levels or ratios of these apolipoproteins has the potential to be used to determine cardiovascular risk.

Various studies investigated this potential and found that testing for apoB or apoA levels, or their ratio, could be a better marker for cardiovascular risk than other markers such as total cholesterol. This includes one study on 175,553 individuals who were followed for 65 months which showed an increase in relative risk of fatal myocardial infarction with an increase in apoB concentration.

Another study involving around 27,000 participants showed that an increase in the ratio of apoA and apoB was linked to myocardial infarction.

Yang, Z. and Zhou, D. M. (2006) Cardiac markers and their point-of-care testing for diagnosis of acute myocardial infarction Clinical Biochemistry https://doi.org/10.1016/j.clinbiochem.2006.05.011

Xu, L-Q. et al. (2018) Early Diagnostic Performance of Heart-Type Fatty Acid Binding Protein in Suspected Acute Myocardial Infarction: Evidence From a Meta-Analysis of Contemporary Studies Heart, Lung and Circulation https://doi.org/10.1016/j.hlc.2017.03.165

bhf.org.uk Heart Failure

Cowie, M. R. et al. (2003) Clinical applications of B-type natriuretic peptide (BNP) testing European Heart Journal https://doi.org/10.1016/S0195-668X(03)00476-7

Gruson, D. (2018) Oxytocin testing and reproductive health: Status and clinical applications Clinical Biochemistry https://doi.org/10.1016/j.clinbiochem.2018.10.016

Dominiczak, M. H. and Caslake, M. J. (2011) Apolipoproteins: metabolic role and clinical biochemistry applications Annals of Clinical Biochemistry: International Journal of Laboratory Medicine https://doi.org/10.1258/acb.2011.011111

Here is the original post:
Cardiovascular Testing Applications of Biochemistry - News-Medical.net

Biochemistry

Automated Biochemistry Analyzers Market by Manufacturers, Regions, Type and Application, Forecast To 2026 Abbott, Danaher, Hitachi, Roche, Siemens -…

The Global Automated Biochemistry Analyzers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) 2020-2026 report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. Automated Biochemistry Analyzers Market research report offers extensive research and analysis of key aspects of the global Automated Biochemistry Analyzers market. The report provides deeper understanding of the competitive landscape and its future scenarios, crucial dynamics, and leading segments of the global Automated Biochemistry Analyzers market. The report also provides accurate PESTLE, SWOT and other types of analysis on the global Automated Biochemistry Analyzers market. The market study has examined the competitive trend apart from offering valuable insights to clients as well as industries. This report concentrate on the global Automated Biochemistry Analyzers status, future forecast, development opportunity, key market and key players.

Major companies listed in the market includes:

AbbottDanaherHitachiRocheSiemensThermo Fisher Scientific

Request for a Sample Report of Automated Biochemistry Analyzers Market: https://www.apexmarketreports.com/Heavy-Industry/global-automated-biochemistry-analyzers-market-by-product-type-635778#inquiry

The report on Global Automated Biochemistry Analyzers Market 2020 cover big geographical, as well as, sub-regions throughout the world. The study objectives of the report are to present the Automated Biochemistry Analyzers development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. The aim of the report is to get premium insights, quality data figures and information in relation to aspects such as market scope, market size, share, and segments such as Types of Products and Services, Application/end use industry, SWOT Analysis and by different emerging by geographies.

Covid-19 Impact Update Global Automated Biochemistry Analyzers Market Research

The report also provides how this industry is likely to be impacted as a result of the global COVID-19 pandemic: market size by revenue is expected to grow xx% in 2020 alone as demand is anticipated to be moderately affected by the outbreak of COVID-19. The downstream companies contend with restricted profit from falling consumer confidence, demand for industry products is expected to slow. Demand from top notch companies and government agencies is expected to rise as they seek more information on COVID-19.

Apart from that, the report also provides valuable differentiating information regarding each of the market segments. These segments are examined further on different fronts such as historical performance, market size contributions, % market share, expected rate of growth.

Request Sample Enquiry Buying

Key Businesses Segmentation or Breakdown covered in Automated Biochemistry Analyzers Market Study

On the Basis of Type

Stationary Biochemistry AnalyzersPortable Biochemistry Analyzers

On the Basis of Application

Hospital and Diagnostic LaboratoriesHome Care, and AcademicResearch Institutes

On the Basis of Region

The report is mainly segmented into several key regions, with sales, revenue, market share and growth rate of Automated Biochemistry Analyzers in these regions, from 2020 to 2027, covering:

Enquire Here for, Report Enquire, Discount and Customization: https://www.apexmarketreports.com/Heavy-Industry/global-automated-biochemistry-analyzers-market-by-product-type-635778#inquiry

The Automated Biochemistry Analyzers Market Key Offering:

Business Strategies

Key strategies in the global Automated Biochemistry Analyzers market like product developments, partnerships, mergers and acquisitions, etc., analysed in this report. The worth of strategic analysis has been rigorously investigated in conjunction with undisputed market challenges. The Automated Biochemistry Analyzers market report delivers conclusion that includes breakdown and data triangulation, consumer needs/customer preference change, research findings, market size estimation, data source. These factors will increase the business overall.

About Us:

We at Apex Market Reports aim to be global leaders in qualitative and predictive analysis as we put ourselves in the front seat for identifying worldwide industrial trends and opportunities and mapping them out for you on a silver platter. We specialize in identifying the calibers of the markets robust activities and constantly pushing out the areas which allow our clientele base in making the most innovative, optimized, integrated and strategic business decisions in order to put them ahead of their competition by leaps and bounds. Our researchers achieve this mammoth of a task by conducting sound research through many data points scattered through carefully placed equatorial regions.

Contact Us:

Apex Market Reports1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 Indiatel: +91-8149441100 (GMT Office Hours)tel: +17738002974sales@apexmarketsreports.com

View original post here:
Automated Biochemistry Analyzers Market by Manufacturers, Regions, Type and Application, Forecast To 2026 Abbott, Danaher, Hitachi, Roche, Siemens -...

Biochemistry

Global Biochemistry Analyzing Systems Market 2020 Technological Strategies, Business Advancements and Top-Vendor Landscape by 2025 – BAVIATION…

A recent market study published by MarketandResearch.biz with the title Global Biochemistry Analyzing Systems Market Growth 2020-2025 is an expert and top to bottom investigation of the market condition with an attention on the market. The report conducts thorough research on the historical, as well as current growth parameters of the market, the growth prospects of the market, are obtained with maximum precision. The report covers key insights available status of the producers and is an important source of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of the 2020-2025 worldwide market covering extremely significant parameters. The market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Executive Summary:

The market report highlights the growth driving factors, opportunities, and challenges that will impact the industry growth in the ensuing years. The report presents an in-depth analysis of key business trends and future market development prospects, key drivers and limitations, the profile of key market players, segmentation, and forecasts. It provides an extensive view of size, trends, demand-side and supply-side trends, and opportunity assessment. The study offers a detailed examination of various market segments to deliver a clear understanding of the revenue prospects of this global Biochemistry Analyzing Systems industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/150398

Our exploration specialists acutely discover the significant aspects of the global market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstances of the global Biochemistry Analyzing Systems market situation. In this report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. With this market report, businesses can acquire details about market drivers and market restraints which assist them to take presumption about reducing or increasing the production of a particular product.

Key players profiled in the report include: Roche, Mindray Medical, Siemens Healthcare, Horiba Medical, EKF Diagnostics, Abbott, Balio Diagnostics, Randox Laboratories, Hitachi, Nihon Kohden Europe, Tianjin MNCHIP Technologies Co., Ltd,

On the basis of product type, the market study incorporates: Full Automatic Systems, Semi-Automatic Systems,

On the basis of application, the market study incorporates: Clinical Diagnostic, Drug Testing, Other

The countries covered in the market report are: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Moreover, the report examines all the key factors influencing the growth of the global Biochemistry Analyzing Systems market, including the demand-supply scenario, pricing structure, profit margins, production, and value chain analysis. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, pricing strategies, innovation possibilities, and much more.

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/150398/global-biochemistry-analyzing-systems-market-growth-2020-2025

Why The Market Report Is Beneficial?

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketandresearch.bizWeb: http://www.marketandresearch.biz

More:
Global Biochemistry Analyzing Systems Market 2020 Technological Strategies, Business Advancements and Top-Vendor Landscape by 2025 - BAVIATION...

Biochemistry

Digital Therapeutics Startup S-Alpha Therapeutics Raises $2.7M in Seed Funding – BioSpace

Dec. 16, 2020 17:00 UTC

SEOUL--(BUSINESS WIRE)-- On November 20th, S-Alpha Therapeutics (S-Alpha Seung Eun Choi, CEO), a digital therapeutics startup, completed a $2.7 Million USD (3 Billion KRW) seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. This seed round follows an initial strategic investment from LegoChem Biosciences in February 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005185/en/

S-Alpha Therapeutics completed a $2.7 Million USD (3 Billion KRW) seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. (Photo: Business Wire)

Hana Ventures led the seed round funding with the expectation of high growth in the digital therapeutics market. The company intends to use funds to execute clinical trials in the US to study their development stage digital therapeutic application intended to treat eye disease.

Dr. Myung Joon Kim, Chief Medical Officer at S-Alpha, leading the team to secure proprietary technologies for the discovery and development of the pipeline and internalization of the technology, commented, The fact that S-Alpha consists of specialists from various areas including domestic and international clinical experts, biochemistry experts, and software application development experts, collaborating to develop digital therapeutics was highly valued by the investors. S-Alpha will continue its effort to develop cutting-edge digital therapeutics in several disease areas.

About S-Alpha Therapeutics, Inc.

S-Alpha Therapeutics Inc., established in July 2019, is a digital therapeutics company with platform technologies that enable digital devices to treat different diseases. S-Alpha has a pipeline of products in the areas of ophthalmology, neuropsychiatry, cancer, and immunology.

S-Alphas lead product, SAT-001, is currently in the process of regulatory submission to start clinical studies in Korea as a therapeutic device for treating eye disease following MFDSs guidance in June 2020. S-Alpha also completed a successful meeting in July 2020 with the USFDA on developing SAT-001 and is preparing to launch clinical studies in the United States. S-Alpha has an extensive product pipeline and collaborates actively with academic and industry partners to develop their R&D programs.

S-Alpha actively engages with the global digital therapeutics community and presented at the Digital Therapeutics East Conference (DTx East 2020) in September 2020 as the first Korean company to be invited to the conference.

S-Alpha is also a member of DTA (DTx Alliance), a non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics.

http://www.salphadtx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005185/en/

The rest is here:
Digital Therapeutics Startup S-Alpha Therapeutics Raises $2.7M in Seed Funding - BioSpace